{"id":601864,"date":"2026-06-30T03:45:38","date_gmt":"2026-06-30T03:45:38","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/601864\/psmatargeted-therapies-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-launch-of-nextgeneration-radioligand-therapies-delveinsight.html"},"modified":"2026-06-30T03:45:38","modified_gmt":"2026-06-30T03:45:38","slug":"psmatargeted-therapies-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-launch-of-nextgeneration-radioligand-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.pennsylvania-magazine.com\/news\/story\/601864\/psmatargeted-therapies-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-launch-of-nextgeneration-radioligand-therapies-delveinsight.html","title":{"rendered":"PSMA-Targeted Therapies Market is Projected to Witness Significant Growth by 2036 Owing to the Launch of Next-Generation Radioligand Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1782453197.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"PSMA-Targeted Therapies Market is Projected to Witness Significant Growth by 2036 Owing to the Launch of Next-Generation Radioligand Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1782453197.jpg\" alt=\"PSMA-Targeted Therapies Market is Projected to Witness Significant Growth by 2036 Owing to the Launch of Next-Generation Radioligand Therapies | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">The market dynamics for PSMA-Targeted Therapies are witnessing significant growth driven by the increasing prevalence of prostate cancer, rising adoption of precision oncology, growing demand for targeted radioligand therapies, and expanding clinical development of next-generation PSMA-directed therapeutics. Additionally, the launch of emerging therapies such as 177Lu-PSMA-I&amp;T (Curium), 177Lu-DOTA-rosopatamab tetraxetan, FPI-2265 (AstraZeneca), and others will further fuel the market.<\/div>\n<p style=\"text-align: justify\">DelveInsight, a leading market research firm, announces the release of its latest report, &#8220;DelveInsight&#8217;s PSMA-Targeted Therapies Market Size, Target Population, Competitive Landscape &amp; Market Forecast &ndash; 2036.&#8221; This comprehensive report provides an in-depth understanding of PSMA-targeted therapies, including target patient population, historical and forecasted market trends, competitive landscape, emerging therapies, pricing trends, and market outlook across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify\">Key Takeaways from the PSMA-Targeted Therapies Market<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">The PSMA-Targeted Therapies market across the 7MM is expected to grow significantly by 2036.<\/p>\n<\/li>\n<li>\n<p>DelveInsight estimates that the 7MM market size is expected to increase from nearly USD 1.0 billion in 2026 to approximately USD 1.6 billion by 2036.<\/p>\n<\/li>\n<li>\n<p>PLUVICTO became the first FDA-approved PSMA-targeted therapy for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) in 2022 and achieved approximately USD 1.4 billion in global revenue during 2024.<\/p>\n<\/li>\n<li>\n<p>In March 2025, the US FDA approved the expanded indication for PLUVICTO in patients with PSMA-positive mCRPC.<\/p>\n<\/li>\n<li>\n<p>In 2025, the United States accounted for nearly 3.9 million prevalent prostate cancer cases, representing the largest eligible patient pool for PSMA-targeted therapies.<\/p>\n<\/li>\n<li>\n<p>Across the 7MM, nearly 2.8 million five-year prevalent prostate cancer cases were estimated in 2025.<\/p>\n<\/li>\n<li>\n<p>In the United States, approximately 70,000 metastatic castration-sensitive prostate cancer (mCSPC) cases and 54,000 prevalent mCRPC cases were estimated in 2025.<\/p>\n<\/li>\n<li>\n<p>Germany accounted for nearly 183,000 localized and locally advanced prostate cancer cases in 2025.<\/p>\n<\/li>\n<li>\n<p>Leading companies including Novartis, Curium, Telix Pharmaceuticals, AstraZeneca, and others are actively developing next-generation PSMA-targeted therapies expected to reshape the treatment landscape during the forecast period.<\/p>\n<\/li>\n<li>\n<p>Promising pipeline therapies include 177Lu-PSMA-I&amp;T, 177Lu-DOTA-rosopatamab tetraxetan (TLX591), FPI-2265, and other novel radioligand therapies.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Keen to know more about the market? Request our sample page at<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psma-targeted-therapy-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">https:\/\/www.delveinsight.com\/report-store\/psma-targeted-therapy-market-forecast<\/a><\/p>\n<p style=\"text-align: justify\">Key Factors Driving the PSMA-Targeted Therapies Market<\/p>\n<p style=\"text-align: justify\">Increasing Burden of Prostate Cancer<\/p>\n<p style=\"text-align: justify\">The rising incidence and prevalence of prostate cancer, particularly advanced and metastatic disease, continue to expand the addressable patient population eligible for PSMA-targeted therapies worldwide.<\/p>\n<p style=\"text-align: justify\">Growing Adoption of Precision Oncology<\/p>\n<p style=\"text-align: justify\">PSMA has emerged as one of the most important biomarkers in prostate cancer. Increasing utilization of PSMA PET imaging and biomarker-driven treatment selection is accelerating the adoption of PSMA-directed therapeutics.<\/p>\n<p style=\"text-align: justify\">Expanding Clinical Success of Radioligand Therapies<\/p>\n<p style=\"text-align: justify\">The commercial success of PLUVICTO has validated PSMA-targeted radioligand therapy as an effective treatment approach for advanced prostate cancer. This has stimulated substantial investment in next-generation beta- and alpha-emitting radiopharmaceuticals.<\/p>\n<p style=\"text-align: justify\">Strong Pipeline of Next-Generation Therapies<\/p>\n<p style=\"text-align: justify\">Several late-stage clinical programs are evaluating improved PSMA-targeted agents with enhanced efficacy, broader treatment eligibility, and reduced toxicity, supporting long-term market expansion.<\/p>\n<p style=\"text-align: justify\">PSMA-Targeted Therapies Competitive Landscape<\/p>\n<p style=\"text-align: justify\">Currently, PLUVICTO (Novartis) is the only globally approved PSMA-targeted radioligand therapy and continues to dominate the market. However, numerous late-stage candidates are expected to significantly intensify competition over the next decade.<\/p>\n<p style=\"text-align: justify\">Several PSMA-targeted therapies in development include:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>177Lu-PSMA-I&amp;T (Curium)<\/p>\n<\/li>\n<li>\n<p>177Lu-DOTA-rosopatamab tetraxetan (TLX591) (Telix Pharmaceuticals)<\/p>\n<\/li>\n<li>\n<p>FPI-2265 (AstraZeneca)<\/p>\n<\/li>\n<li>\n<p>and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">These investigational therapies utilize diverse approaches including beta-emitting radioligands, alpha-emitting radioconjugates, monoclonal antibody-based radioimmunotherapy, and next-generation targeted radionuclide delivery systems to improve efficacy while minimizing toxicity to healthy tissues.<\/p>\n<p style=\"text-align: justify\">Discover more about therapies set to grab major PSMA-Targeted Therapies market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psma-targeted-therapy-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">PSMA-Targeted Therapies Competitive Landscape<\/a><\/p>\n<p style=\"text-align: justify\">Recent Developments in the PSMA-Targeted Therapies Market<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>In February 2026, Curium, together with PeptiDream and PDRadiopharma, announced that the first patient had been dosed in the registrational clinical trial evaluating 177Lu-PSMA-I&amp;T in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer.<\/p>\n<\/li>\n<li>\n<p>In January 2026, Telix Pharmaceuticals announced that the first patient had been dosed in the Phase III registration study evaluating TLX591-Px (ILLUCCIX) for prostate cancer imaging in Japan.<\/p>\n<\/li>\n<li>\n<p>In March 2025, Novartis announced that the US FDA approved the expanded indication for PLUVICTO in patients with PSMA-positive metastatic castration-resistant prostate cancer.<\/p>\n<\/li>\n<li>\n<p>In May 2025, Lantheus announced discontinuation of the PNT2002 development program following final SPLASH study results showing no overall survival benefit in pre-chemotherapy mCRPC.<\/p>\n<\/li>\n<li>\n<p>AstraZeneca continues to evaluate FPI-2265, an actinium-225-based PSMA-targeted radioconjugate, in the ongoing Phase II TATCIST clinical trial for patients with PSMA-positive metastatic castration-resistant prostate cancer.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">What are PSMA-Targeted Therapies?<\/p>\n<p style=\"text-align: justify\">Prostate-Specific Membrane Antigen (PSMA)-targeted therapies are an emerging class of precision medicines designed to selectively target prostate cancer cells that overexpress PSMA, a cell-surface protein highly expressed in advanced prostate cancer. These therapies deliver radioactive isotopes directly to tumor cells, enabling precise destruction of cancer while minimizing damage to surrounding healthy tissues. The approval of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) established PSMA-targeted radioligand therapy as a transformative treatment option for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). With multiple next-generation radioligand therapies currently in clinical development, the treatment landscape is expected to evolve significantly during the forecast period.<\/p>\n<p style=\"text-align: justify\">PSMA-Targeted Therapies Epidemiology Segmentation<\/p>\n<p style=\"text-align: justify\">The PSMA-Targeted Therapies epidemiology section provides insights into the historical and current treatment-eligible patient pool and forecasted trends across the leading markets. The report provides epidemiological analysis for the study period 2022&ndash;2036, segmented into:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Cases of Prostate Cancer for PSMA-Targeted Therapies<\/p>\n<\/li>\n<li>\n<p>Total Eligible Patient Pool for PSMA-Targeted Therapies in Prostate Cancer<\/p>\n<\/li>\n<li>\n<p>Total Treated Cases in Prostate Cancer for PSMA-Targeted Therapies<\/p>\n<\/li>\n<li>\n<p>Five-year Prevalent Cases of Prostate Cancer<\/p>\n<\/li>\n<li>\n<p>Age-specific Cases of Prostate Cancer<\/p>\n<\/li>\n<li>\n<p>Clinical Stage-specific Cases of Prostate Cancer<\/p>\n<\/li>\n<li>\n<p>Metastatic Castration-sensitive Prostate Cancer (mCSPC)<\/p>\n<\/li>\n<li>\n<p>Metastatic Castration-resistant Prostate Cancer (mCRPC)<\/p>\n<\/li>\n<li>\n<p>Non-metastatic Castration-sensitive Prostate Cancer (nmCSPC)<\/p>\n<\/li>\n<li>\n<p>Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Scope of the PSMA-Targeted Therapies Market Report<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Therapeutic Assessment: Current marketed and emerging PSMA-targeted therapies<\/p>\n<\/li>\n<li>\n<p>PSMA-Targeted Therapies Market Dynamics: Key Market Forecast Assumptions, Pricing Trends, Market Outlook, and Therapy Uptake<\/p>\n<\/li>\n<li>\n<p>Key Companies: Novartis, Curium, Telix Pharmaceuticals, AstraZeneca, and others<\/p>\n<\/li>\n<li>\n<p>Key Therapies: PLUVICTO (Lutetium Lu-177 Vipivotide Tetraxetan), 177Lu-PSMA-I&amp;T, 177Lu-DOTA-rosopatamab tetraxetan (TLX591), FPI-2265, and others<\/p>\n<\/li>\n<li>\n<p>Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis, Competitive Benchmarking, and Market Entry Strategies<\/p>\n<\/li>\n<li>\n<p>Target Population Assessment, KOL Views, Analyst Views, Pricing Trends, Market Access, and Reimbursement Analysis<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">To know more about companies working in the PSMA-Targeted Therapies market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psma-targeted-therapy-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">PSMA-Targeted Therapies Competitive Landscape and Emerging Therapies<\/a><\/p>\n<p style=\"text-align: justify\">Table of Contents<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>PSMA-Targeted Therapies Market Report Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary<\/p>\n<\/li>\n<li>\n<p>Key Events<\/p>\n<\/li>\n<li>\n<p>Upcoming Key Catalysts<\/p>\n<\/li>\n<li>\n<p>Key Conference and Meeting Insights<\/p>\n<\/li>\n<li>\n<p>News Flow<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Market Forecast Methodology<\/p>\n<\/li>\n<li>\n<p>PSMA-Targeted Therapies Market Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Clinical Landscape<\/p>\n<\/li>\n<li>\n<p>Background and Overview<\/p>\n<\/li>\n<li>\n<p>Treatment Guidelines<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Patient Population<\/p>\n<\/li>\n<li>\n<p>Marketed Therapy<\/p>\n<\/li>\n<li>\n<p>Emerging Therapies<\/p>\n<\/li>\n<li>\n<p>Seven Major Market Analysis<\/p>\n<\/li>\n<li>\n<p>Pricing Trends<\/p>\n<\/li>\n<li>\n<p>Analogue Assessment<\/p>\n<\/li>\n<li>\n<p>Therapy Uptake<\/p>\n<\/li>\n<li>\n<p>Country-wise Market Analysis (2022&ndash;2036)<\/p>\n<\/li>\n<li>\n<p>Unmet Needs<\/p>\n<\/li>\n<li>\n<p>SWOT Analysis<\/p>\n<\/li>\n<li>\n<p>KOL Views<\/p>\n<\/li>\n<li>\n<p>Market Access and Reimbursement<\/p>\n<\/li>\n<li>\n<p>Summary of Pricing and Reimbursement Policy Developments<\/p>\n<\/li>\n<li>\n<p>Appendix<\/p>\n<\/li>\n<li>\n<p>Report Methodology<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<li>\n<p>About DelveInsight<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">About DelveInsight<\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform, PharmDelve.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kirti Sharma<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=psmatargeted-therapies-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-launch-of-nextgeneration-radioligand-therapies-delveinsight\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=psmatargeted-therapies-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-launch-of-nextgeneration-radioligand-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The market dynamics for PSMA-Targeted Therapies are witnessing significant growth driven by the increasing prevalence of prostate cancer, rising adoption of precision oncology, growing demand for targeted radioligand therapies, and<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/601864"}],"collection":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/comments?post=601864"}],"version-history":[{"count":0,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/601864\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/media?parent=601864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/categories?post=601864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/tags?post=601864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}